Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Ivor_Royston
|
| gptkbp:clinicalTrialPhase |
Phase 2 trial for nanatinostat
|
| gptkbp:collaboratesWith |
gptkb:National_Cancer_Institute
|
| gptkbp:developedBy |
targeted therapies for EBV-associated cancers
|
| gptkbp:focusesOn |
oncology
virus-associated cancers |
| gptkbp:foundedYear |
2014
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Viracta Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:numberOfEmployees |
approximately 50 (as of 2023)
|
| gptkbp:product |
nanatinostat
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
epigenetic therapies
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
VIRX
|
| gptkbp:website |
https://www.viracta.com/
|
| gptkbp:bfsParent |
gptkb:Sorrento_Mesa
|
| gptkbp:bfsLayer |
8
|